Lepirudin therapy and clinical events
Parameter . | No. patients/no. total (%) . |
|---|---|
| Mean dose (excluding first bolus intravenous dose)* | |
| Less than 0.04 mg/kg/h | 49/163 (30.1) |
| 0.04 to 0.07 mg/kg/h | 43/163 (26.4) |
| 0.07 to 0.15 mg/kg/h | 68/163 (41.7) |
| More than 0.15 mg/kg/h | 3/163 (1.8) |
| Mean aPTT prolongation relative to baseline value | |
| Less than 1.5 | 2/165 (1.2) |
| 1.5-2.5 | 77/165 (46.6) |
| More than 2.5 | 86/165 (52.2) |
| Thrombotic event | 25/181 (13.8)† |
| Major bleeding | 37/181 (20.4)‡ |
Parameter . | No. patients/no. total (%) . |
|---|---|
| Mean dose (excluding first bolus intravenous dose)* | |
| Less than 0.04 mg/kg/h | 49/163 (30.1) |
| 0.04 to 0.07 mg/kg/h | 43/163 (26.4) |
| 0.07 to 0.15 mg/kg/h | 68/163 (41.7) |
| More than 0.15 mg/kg/h | 3/163 (1.8) |
| Mean aPTT prolongation relative to baseline value | |
| Less than 1.5 | 2/165 (1.2) |
| 1.5-2.5 | 77/165 (46.6) |
| More than 2.5 | 86/165 (52.2) |
| Thrombotic event | 25/181 (13.8)† |
| Major bleeding | 37/181 (20.4)‡ |
Recommended dose: administration of a 0.4 mg/kg bolus dose followed by a continuous intravenous dose of 0.15 mg/kg/h adjusted to maintain an aPTT between 1.5 and 2.5 times baseline value. Mean dose (excluding first bolus intravenous dose) ± SD was 0.06 ± 0.04. Median treatment duration was 7.7 days (range, 3.6-14.0)
Including one limb amputation
Including 7 fatal bleeds